• Four differentiated therapeutic programs progressing through clinical studies in immuno-oncology and autoimmune diseases
  • OSE’s partnership business model based on innovative products; Multiple validating partnering milestones generated €35 million in non-dilutive funds from April 2018 to March 2019
  • Turnover of €24.5 million and net profit of €5.5 million
  • 2018 year-end cash position of €12.4 million and additional milestone payments from Servier and Boehringer Ingelheim received in 2019 provide funding until end of 2020

NANTES, France, March 28, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today reported its consolidated annual financial results as of December 31, 2018 and provided an update on key achievements as well as the company’s outlook for its agonist and antagonist immunotherapies for cancers and autoimmune diseases.

Alexis Peyroles, chief executive officer of OSE Immunotherapeutics said, "OSE Immunotherapeutics achieved a number of important milestones in 2018, including expanding the clinical investigation of our lead product Tedopi, which is now being studied in Phase 3 and Phase 2 trials. We have further validated our business model by signing a landmark partnership deal with Boehringer Ingelheim for  BI 765063 (OSE-172). In addition, we regained full control of FR104, a Phase 2-ready therapeutic candidate with broad potential to treat autoimmune diseases and secured preclinical validation of mechanisms of action for OSE-127 and BI 765063, both now in clinical phase status. These achievements, with multiple first- or best-in-class assets in clinical testing in multiple indications, provide a solid foundation to further accelerate OSE’s growth as an emerging leader in the immuno-oncology and autoimmune spaces in 2019."

KEY ACHIEVEMENTS

  • Tedopi® (neoepitopes) 
    -- Progressed ongoing Phase 3 clinical trial in non-small cell lung cancer (NSCLC) after failure with PD-1/PD-L1 immune checkpoint inhibitors.
    -- 
    Received Clinical Trial Authorization (CTA) for a Phase 2 trial in pancreatic cancer in combination with checkpoint inhibitor Opdivo®.
     
  • BI 765063/OSE-172 (selective SIRPa-antagonist and myeloid checkpoint inhibitor)
    -- 
    Entered global immuno-oncology agreement with Boehringer Ingelheim to develop BI 765063 in solid tumors. Assuming all milestones are met, OSE stands to receive more than €1.1 B.
    -- 
    Received CTA for a Phase 1  trial in advanced solid tumours.
    -- 
    Set to receive milestone payments of a total of €15 M upon CTA receipt for the Phase 1 trial and the upcoming first dosing of a patient.

  • BICKI®, novel bispecific checkpoint inhibitor platform technology
    -- 
    Unveiled a new bispecific fusion protein platform built on the key backbone component anti-PD-1 and targeting innovative targets.

  • OSE-127 (IL-7R antagonist)
    -- 
    Received CTA for a Phase 1 trial for the treatment of autoimmune diseases and announced that the first healthy volunteers were dosed.
    -- 
    Awarded milestone payment of €10 M (€12 M VAT included) upon exercise of the first option exercised by Servier under the two-step option within the global license agreement.

FINANCIAL HIGHLIGHTS

  • Turnover of €24.5 M due to the signature of a global license and collaboration agreement with Boehringer Ingelheim in April 2018 and the method of revenue recognition used for Servier upfront under the license agreement.
  • Net profit of €5.5 M including a research tax credit of €4.8 M.
  • Available cash as of December 31, 2018 of €12.4 M.  Additional €10 M cash revenues received in early 2019 due to milestone payments related to partnerships with Servier; Additional cash influx of €15 M expected from Boehringer Ingelheim in the form of a milestone payment upon dosing of first patient in the Phase 1 trial of BI 765063 (OSE-172).
  • Financial viability until end of 2020.

Key 2018 Achievements

Tedopi®, combination of optimized neoepitopes that induce specific T lymphocyte activation in immuno-oncology, in advanced lung cancer and in pancreatic cancer

  • Progressed an ongoing Phase 3 trial in patients with advanced and metastatic NSCLC who have failed a previous treatment with immune checkpoint inhibitors in Europe, in the U.S. and in Israel.
  • Received a €435k grant from Bpifrance through the Eurostars European Programme to lead a research program within a consortium of five partners. The project aims to validate an immune algorithm specific to Tedopi® and establish precision medicine targeting for the product. It will be conducted in conjunction with the Phase 2 clinical trial for Tedopi® in pancreatic cancer.
  • Received CTA by the French health agency (November 2018) for a Phase 2 trial evaluating Tedopi® in combination with Bristol-Myers Squibb’s Opdivo® (nivolumab), an immune checkpoint inhibitor, versus Folfiri (a combination chemotherapy with folinic acid, fluorouracil and irinotecan) in advanced or metastatic pancreatic cancer. Oncology group GERCOR is sponsoring the clinical trial as part of PRODIGE intergroup.

BI 765063 (OSE-172), SIRPa antagonist and checkpoint inhibitor targeting suppressive myeloid/macrophage cells, in various solid tumors

  • Entered into a global license and collaboration agreement with Boehringer Ingelheim in April 2018 to develop checkpoint inhibitor BI 765063 (OSE-172) in advanced solid tumors.
  • In March 2019, OSE was granted French and Belgian clinical trial authorization (CTA) to initiate a Phase 1 clinical trial of BI 765063 administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a lymphocyte T checkpoint inhibitor.
  • Under the terms of the agreement, OSE has received a €15 M upfront payment from Boehringer Ingelheim; the clinical trial authorization received in March 2019 and the upcoming first dosing of a patient has triggered milestone payments of a total of €15 M. OSE Immunotherapeutics stands to receive from Boehringer Ingelheim more than €1.1 B upon reaching pre-specified development, registration and sales milestones, plus royalties on worldwide net sales. 

BiCKI® platform, a novel bispecific checkpoint inhibitor platform targeting PD-1 and innovative targets

  • Disclosed its novel bispecific checkpoint inhibitor (BiCKI®) platform at the World Immunotherapy Congress (March 2019). This bispecific fusion protein platform is built on the key backbone component anti-PD-1 (OSE-279) and targeting innovative targets. BiCKI® represents the second generation of PD-(L)1 inhibitors that have been used to increase antitumor efficacy in hard to treat cancers by addressing untapped immune evasion mechanisms.

OSE-127, humanized monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R), in inflammatory bowel diseases

  • Received Belgian CTA for a Phase 1 clinical trial (November 2018) for the treatment of autoimmune diseases and first healthy volunteers enrolled and dosed (December 2018).
  • First option exercised under the two-step global option and license agreement exercised by Servier (February 2019) for clinical development and potential commercialization of OSE-127 to treat autoimmune diseases, which triggered a €10 M (€12 M VAT included) milestone payment to OSE from Servier. 
  • Published peer-reviewed article in Nature Communications highlighting the differentiated mechanism of action of OSE-127 as a full-antagonist of IL-7R that shows antigen-specific blockade of memory T cells

FR104, CD28-antagonist, in rheumatoid arthritis

  • Regained the worldwide rights to FR104 from Janssen Biotech, Inc. (November 2018) effective December 31, 2018. Janssen’s decision to return the program to OSE Immunotherapeutics was based on its own internal strategic review and prioritization of its portfolio. OSE recovered FR104 all intellectual property rights that had been licensed to Janssen, data, filings and materials developed by Janssen relating to the FR104 program.
  • OSE is currently evaluating the best options for continuing a sustainable development of FR104 including worldwide partnering opportunities. Positive results from FR104’s Phase 1 proof of clinical concept study taken together with the preclinical safety profile and efficacy data in multiple preclinical models of autoimmune/inflammatory diseases further support continued clinical development of this Phase 2 ready asset.

GOVERNANCE

  • Appointment of Dominique Costantini as chairman of the board of directors and appointment of Alexis Peyroles as chief executive officer.

2018 ANNUAL RESULTS

Meeting of Board of Directors of OSE Immunotherapeutics was held on March 28, 2019. Following the opinion of the Audit Committee, the Board approved the annual and consolidated financial statements prepared under IFRS at 31 December 2018.

The key figures of the 2018 consolidated annual results are reported below (and presented in the attached tables):

In k€12/31/201812/31/2017
Current operating result4 974-12 626
Operating result4 847-12 626
Net result5 490-10 503
Available cash*12 43312 528
Consolidated balance sheet76 90377 353

As of December 31, 2018, available cash* amounted to €12.4 M. In addition, 2018 research tax credits amounted to €4.8 M.

During the first semester of 2019, additional cash influx of €25 M will be generated by milestone payments related to partnerships (€15 M from Boehringer Ingelheim upon CTA for the Phase 1 trial with BI 765063 and upcoming first patient dosed and €10 M from Servier upon exercising of the first option under the two-step option within global license agreement). 

This available cash will enable the Company to finance its  clinical development costs and R&D costs on earlier stage products.

Operating expenses amounted to €19.5 M (€19.3 M in 2017), of which 77 % are related to R&D. R&D expenses were up €15.1 M, in line with the broadening and progress of OSE’s pipeline.

The consolidated balance sheet amounted to €76.9 M compared to €77.4 M as of December 31, 2017, which is quite stable.

* Cash and cash equivalents and Current financial assets

ABOUT OSE Immunotherapeutics 
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company has a diversified first-in-class clinical portfolio consisting of several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. The most advanced therapeutic-candidate, Tedopi®, is a proprietary combination of 10 neo-epitopes aimed at stimulating T-lymphocytes and is currently in Phase 3 development in non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure (anti PD-1 and anti PD-L1) and in Phase 2 testing in pancreatic cancer in combination with checkpoint inhibitor Opdivo®. FR104 (an anti-CD28 mAb) has successfully completed Phase 1 testing and has potential to treat autoimmune diseases. BI 765063 (OSE-172) (anti-SIRPa monoclonal antibody) is under a license and collaboration agreement with Boehringer Ingelheim ; this checkpoint inhibitor has received CTA from French and Belgian health authorities for a Phase 1 clinical trial in multiple cancer indications. BiCKI® is a bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) and targeting innovative targets. OSE-127 (monoclonal antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor) is partnered with Servier under an option agreement up to the completion of a Phase 2 clinical trial planned in autoimmune bowel diseases; in parallel, Servier plans a development in the Sjögren syndrome. OSE-127 is currently under Phase 1 clinical trial.

Click and follow us on Twitter and Linkedln

https://twitter.com/OSEIMMUNO
https://www.linkedin.com/company/10929673

Contacts

OSE ImmunotherapeuticsU.S. Media: LifeSci Public Relations
Sylvie DétryDarren Opland, Ph.D.
Sylvie.detry@ose-immuno.com darren@lifescipublicrelations.com 
+33 153 198 757+1 646 627 8387
  
French Media: FP2COMU.S. and European Investors
Florence PortejoieChris Maggos 
fportejoie@fp2com.fr chris@lifesciadvisors.com
+33 607 768 283+41 79 367 6254

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 26 April 2018, including the annual financial report for the fiscal year 2017, available on the OSE Immunotherapeutics’ website.

Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

APPENDICES

CONSOLIDATED PROFIT & LOSS
   
P&L IN KEUROS12/31/201812/31/2017
Turnover24 456 6 682 
Other operating income0 0 
Total Revenues24 456 6 682 
Research and development expenses(15 057)(14 641)
Overhead expenses(3 448)(3 161)
Expenses related to shares payments(977)(1 505)
OPERATING PROFIT/LOSS - CURRENT4 974 (12 626)
Other operating products (badwill)0 0 
Other operating expenses(127)0 
OPERATING PROFIT/LOSS4 847 (12 626)
Financial products86 70 
Financial expenses(227)(185)
PROFIT/LOSS BEFORE TAX4 707 (12 741)
Income Tax783 2 238 
NET PROFIT/LOSS5 490 (10 503)
Of which consolidated net result attributable to shareholders5 490 (10 503)
Net earnings attributable to shareholders   
Weighted average number of shares outstanding14 634 760 14 360 869 
Basic earnings per share0,38 (0,73)
Diluted earnings per share0,35  


IN K€ 2018 2017 
NET RESULT 5 490 (10 503 )
Amounts to be recycled in the income statement:   
Unrealized gains on securities available for sale, net of tax  
Currency conversion difference(42)92  
   
Amounts not to be recycled in the income statement:   
Actuarial gains and losses on post-employment benefits 12  
Other comprehensive income in the period(30)93   
GLOBAL PROFIT/LOSS 5 460 (10 410 )



CONSOLIDATED BALANCE SHEET

ASSETS IN KEUROS12/31/201812/31/2017
Intangible assets52 600 52 600 
Tangible assets904 429 
Financial assets103 77 
Deferred tax assets272 261 
TOTAL NON CURRENT ASSETS53 879 53 367 
Trade receivables2 253 127 
Other current assets3 834 5 715 
Tax accounts receivables4 504 5 615 
Current financial assets2 861 2 882 
Cash and cash equivalents9 573 9 646 
Total current assets23 024 23 986 
TOTAL ASSETS 
76 903 77 353 
    
EQUITY & LIABILITIES in K€ 12/31/201812/31/2017
   
SHAREHOLDERS’ EQUITY   
Stated capital 2 963 2 898  
Share premium 21 708 21 743  
Merger premium 26 827 26 855  
Treasury stock (168)(191)
Reserves and retained earnings4 934 14 644 
Consolidated result5 490 (10 503)
TOTAL SHAREHOLDERS’ EQUITY 61 754 55 446 
NON-CURRENT DEBTS  
Non-current financial liabilities3 832 4 296 
Non-current deferred tax liabilities 2 010 2 866 
Non-current provisions 233 247  
TOTAL NON-CURRENT DEBTS 6 074 7 410   
CURRENT DEBTS   
Current financial liabilities628 589  
Trade payables6 555 8 776  
Corporate income tax liabilities 86  
Social and tax payables1 231 1 060  
Other debts and accruals 575 4 071 
TOTAL CURRENT DEBTS9 075 14 497 
TOTAL LIABILITIES76 903 77 353 


CONSOLIDATED CASH FLOW STATEMENT

 In kEuros 2018 2017 
 Consolidated result5 490 (10 503)
  +/-Depreciation, amortization and provision expenses116 123 
-Badwill 0 0 
+Derecognition of asset0 0 
  +/-Shares based payments (1)845 1 373 
  +/-Other calculated income and expenses0 0 
 Cash flow before tax6 450 (9 007)
  +Financial charges0 0 
-Income tax expenses (included deferred tax) (783)(2 238)
 CASH FLOW FROM OPERATING ACTIVITIES (A)5 668 (11 245)
-Paid taxes  
  +/-Working capital variation (2)(4 590)3 249 
 CASH FLOW FROM INVESTING ACTIVITIES (D)1 077 (7 996)
  -Tangible assets increase(593)(353)
+/Current financial assets variation22 (2)
  +/-Non-current financial assets variation40 (10)
  +/-Change in scope of consolidation0 0 
  +/-Loans and advances variation(27)66 
 CASH FLOW FROM INVESTING ACTIVITIES (E)(558)(299)
  +Capital increase (including share premium)23 17 
  +/-Own shares transactions(67)(67)
  -Capital increase and merger expenses0 0 
  +Warrant subscription (3)7 18 
  +Loans subscription0 3 564 
  -Loans repayment(485)(465)
  -Financial charges(71)(11)
  +/-Other flows from financing activities0 0 
 CASH FLOW FROM FINANCING ACTIVITIES (F)(592)3 056 
  +/-Currency translation transactions (G)0 0 
 CASH VARIATION H = (D + E + F + G)(73)(5 239)
 CASH OPENING BALANCE (I)9 646 14 885 
 CASH CLOSING BALANCE (J)9 573 9 646 
 DIFFERENCE : H (J-I)0 0 

(1) Warrants and free shares awards granted in 2018 and valuated for 845 K€
(2) Mainly explained by :

  • Decrease of trade receivable for 2 126 k€
  • Increase of other current assets for 1 881k€
  • Increase of tax accounts receivable  for 1 111 k€
  • Adjustment of deferred tax for 783 k€
  • Decrease of other non-current liabilities for 857k€
  • Increase of non-current financial debt for 134k€
  • Decrease of trade accounts payable for 2 221k€
  • Increase of social and tax payable for 171 k€
  • Decrease of other debts for 3 496 k€
  • Deferred tax income for 74k€

(3) 12 000 warrants subscripted with an unit value of 0.60€ 

As of December 31, 2018 the available cash is as follows:

In kEuros12/31/201812/31/2017
Cash & equivalents according to IAS 79 5739 646
Current financial assets2 8612 882
Available Cash12 43312 528